natgillin/translations-raw huggingface dataset:
Specific in vivo medicinal product interaction studies have not been performed.
Specifične študije in vivo medsebojnega delovanja zdravil niso bile opravljene.
Effects of other medicinal products on duloxetine Antacids and H2 antagonists: co-administration of YENTREVE with aluminium- and magnesium- containing antacids or with famotidine had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose.
Učinki drugih zdravil na duloksetin Antacidi in antagonisti H2: sočasno dajanje zdravila YENTREVE z antacidi, vsebujočimi aluminij in magnezij, ali s famotidinom ni imelo pomembnega učinka na hitrost ali obseg absorpcije duloksetina po dajanju 40 mg peroralnega odmerka.
Inhibitors of CYP1A2: because CYP1A2 is involved in duloxetine metabolism, concomitant use of YENTREVE with potent inhibitors of CYP1A2 is likely to result in higher concentrations of duloxetine.
Zaviralci CYP1A2: ker je CYP1A2 vpleten v presnovo duloksetina, je verjetno, da bo sočasna uporaba zdravila YENTREVE z močnimi zaviralci CYP1A2 povzročila višje koncentracije duloksetina.
Therefore YENTREVE should not be administered in combination with potent inhibitors of CYP1A2 like fluvoxamine (see section 4.3).
Zato zdravila YENTREVE ne smemo dajati skupaj z močnimi zaviralci CYP1A2, kot je fluvoksamin (glejte poglavje 4. 4).
As with other serotoninergic medicinal products, discontinuation symptoms may occur in the neonate after maternal duloxetine use near term.
Po maternalni uporabi duloksetina proti koncu nosečnosti, se lahko pri novorojenčkih pojavijo odtegnitveni simptomi.
YENTREVE should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.
Zdravilo YENTREVE naj se v nosečnostu uporablja le, če možna korist upravičuje možno tveganje za plod.
6 Table 1 gives the adverse reactions observed from spontaneous reporting and in placebo-controlled clinical trials (comprising a total of 7976 patients, 4370 on duloxetine and 3606 on placebo) in SUI and other lower urinary tract disorders.
Preglednica 1 prikazuje neželene učinke, ki so jih opažali v spontanih poročanjih in v s placebom kontroliranih kliničnih preskušanjih (skupno 7. 976 bolnic, 4. 370 jih je jemalo duloksetin, 3. 606 jih je dobilo placebo) za zdravljenje SUI ali drugih bolezni spodnjih sečil.
Very common Investigations
Zelo pogosti Preiskave
Creatine phosphokinase increased
Zvišanje kreatinin - fosfokinaze
Palpitations Nervous System Disorders
Bolezni živčevja
Tachycardia
Palpitacije
Supra- ventricular arrhythmia, mainly atrial fibrillation
Tahikardija
Poor quality sleep Disturbance in attention Nervousness Dysgeusia
Supra - ventrikularna aritmija, zlasti atrijska fibrilacija
Serotonin syndrome Psychomotor restlessness Convulsions Akathisia Extrapyramidal symptoms
Glavobol Omotica Tremor Letargija Zaspanost Parestezija
Blurred vision Ear and Labyrinth Disorders
Slaba kvaliteta spanja Motnje pozornosti Živčnost Disgevzija
Visual disturbance Mydriasis
Diskinezija Mioklonus
Glaucoma
Serotoninski sindrom Psihomotoričn i nemir Konvulzije Akatizija Ekstrapiramid ni simptomi
Yawning
Glavkom
Nausea Diarrhoea (23.3%) Vomiting Dry mouth Dyspepsia
Ušesne bolezni, vključno z motnjami labirinta Tinitus1 Vrtoglavica Ušesna bolečina Bolezni dihal, prsnega koša in mediastinalnega prostora Bolezni prebavil
Haematochezia
Zehanje
Gastrointestina l haemorrhage
Epistaksa Stisnjeno grlo
Very common
Navzea (23, 3%) Suha usta (11, 9%) Zaprtje (10, 3%) Bolezni sečil
Uncommon
Driska Bruhanje Dispepsija
Rare
Gastroenteritis Stomatitis Gastritis Napenjanje Kolcanje Slab zadah
Very Rare
Hematohezija
Frequency not known
Gastrointestina lna krvavitev
(11.9%) Constipation (10.3%) Renals and Urinary Disorders
Odlašanje uriniranja Disurija Nokturija Nenormalen vonj urina
Flatulence Eructation Breath odour
Slabši curek urina Poliurija
Rash Increased tendency to bruise Night sweats Cold sweat
Izpuščaj Povečano nagnjenje k modricam Nočno znojenje Hladen znoj
Photo- sensitivity reactions Dermatitis contact Urticaria
Fotosenzitivno stne reakcije Kontaktni dermatitis Urtikarija
Stevens- Johnson Syndrome Angioneurotic oedema
Stevens - Johnsonov sindrom Angionevrotič ni edem
Muscoskeletal and connective tissue disorders Endocrine disorders Metabolism and Nutrition Disorders
Bolezni mišično- skeletnega sistema in vezivnega tkiva Bolezni endokrinega sistema Presnovne in prehranske motnje
Muscle spasm Muscle tightness Musculo- skeletal pain Trismus Hypo- thyroidism
Mišični krč Napetost mišic Mišično - skeletna bolečina Trizem Hipotiroidize m
Appetite decreased Infections and infestations
Zmanjšanje apetita Infekcijske in parazitske bolezni Žilne bolezni
Dehydration
Dehidracija Laringitis Sinkopa2
Hyperglycemia (reported especially in diabetic patients) SIADH Hyponatremia
Hiperglikemija (poročana zlasti pri diabetičnih bolnikih) Sindrom neustreznega izločanja antidiuretičneg a hormona Hiponatriemija
Hypertensive crisis Orthostatic hypotension2Pe ripheral coldness
Hipertenzivna kriza Ortostatska hipotenzija2 Hladni periferni deli
Abdominal pain Pruritus Weakness Chills
Bolečina v trebuhu Srbež
Malaise Feeling abnormal Feeling hot Thirst
Bolehnost Občutek vročine
Immune system disorders
Šibkost Mrzlica
Hyper- sensitivity
Neobičajno počutje Žeja
Anaphylactic reaction
Bolezni imunskega
8 Very common
sistema
Common
Preobčutljivost
Uncommon
Anafilaktična reakcija
Rare
Bolezni jeter, žolčnika in žolčevodov Motnje reprodukcije in dojk Psihiatrične motnje
Very Rare
Hepatitis3 Zvišani jetrni encimi (ALT, AST, alkalna fosfataza) Akutna okvara jeter Menopavzalni simptomi Ginekološka krvavitev
Frequency not known
Odpoved jeter Zlatenica
disorder Hepato-biliary disorders
Nespečnost Anksioznost
Hepatitis3 Elevated liver enzymes (ALT, AST, alkaline phosphatase) Acute liver injury
Dezorientacija Halucinacije Nenavadne
Hepatic failure Jaundice
Samomorilno obnašanje
Reproductive System and Breast Disorders Menopausal symptoms Gynaecological haemorrhage Psychiatric Disorders 11
Motnje spanja sanje Agitacija Apatija
Insomnia AnxietySleep disorder Agitation Libido decreased
Razmišljanje o samomoru4
Disorientation Hallucinations Abnormal dreams Apathy BruxismOrgas m abnormal
Zmanjšanje Bruksizem libida Nenormalen orgazem
Suicidal behaviour Suicidal ideation4 Mania Aggression and anger5
Manija Agresija in jeza5
2 Cases of orthostatic hypotension and syncope have been reported especially at the initiation of treatment 23 See section 4.4 4 Cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation (see section 4.4) 5 Cases of aggression and anger have been reported particularly early in treatment of after treatment discontinuation.
5 O primerih agresije in jeze so poročali zlasti ob začetku zdravljenja in po prekinitvi zdravljenja.
9 Cases of overdoses, alone or in combination with other medicinal products, with duloxetine doses of 4800mg were reported.
Poročali so o primerih prevelikega odmerjanja duloksetina samega ali v kombinaciji z drugimi zdravili, s 4800 mg odmerki duloksetina.
Signs and symptoms of overdose (duloxetine alone or with mixed medicinal products) included somnolence, coma, serotonin syndrome, seizures, vomiting and tachycardia.
Znaki in simptomi prevelikega odmerjanja (duloksetina samega ali v kombinaciji z drugimi zdravili) so vključevali zaspanost, komo, serotoninski sindrom, epileptične napade, bruhanje in tahikardijo.
Using a global improvement scale (PGI), significantly more women using duloxetine considered their symptoms of stress incontinence to be improved with treatment compared with women using placebo (64.6% versus 50.1%, p < .001).
10 so jemale duloksetin, ocenilo svoje simptome stresne inkontinence za izboljšane z zdravljenjem, v primerjavi z ženskami, ki so prejemale placebo (64, 6% v primerjavi s 50, 1%, p < 0, 001).
10 YENTREVE and Prior Continence Surgery: there are limited data that suggest that the benefits of YENTREVE are not diminished in women with stress urinary incontinence who have previously undergone continence surgery.
Zdravilo YENTREVE in predhodno kirurško zdravljenje inkontinence: omejeni podatki kažejo, da koristi zdravila YENTREVE pri bolnicah s stresno urinsko inkontinenco, ki so bile predhodno operirane zaradi inkontinence, niso zmanjšane.
YENTREVE and Pelvic Floor Muscle Training (PFMT): during a 12-week blinded, randomised, controlled study, YENTREVE demonstrated greater reductions in IEF compared with either placebo treatment or with PFMT alone.
Zdravilo YENTREVE in trening mišic medeničnega dna (Pelvic Floor Muscle Training, PFMT): v 12 - tedenski slepi, randomizirani, kontrolirani študiji je zdravilo YENTREVE pokazalo večja znižanja IEF v primerjavi ali s placebom ali s samim PFMT.
11 milk are about one-fourth those in plasma.
Odlaganje duloksetina so preučevali pri 6 doječih ženskah v obdobju najmanj 12 tednov po porodu.
YENTREVE 20 mg hard gastro-resistant capsules.
YENTREVE 20 mg trde gastrorezistentne kapsule
The capsule has an oOpaque blue body, imprinted with ‘ 20 mg’ and an opaque blue cap, imprinted with ‘ 9544’.
Kapsula ima neprozorno modro telo z vtisnjenim napisom ‘ 20 mg ’ ter neprozoren moder pokrovček z vtisnjeno oznako ‘ 9544 ’.
The safety and efficacy of duloxetine in patients in these age groups have not been studied.
14 Otroci in mladostniki Varnosti in učinkovitosti duloksetina pri bolnikih v teh starostnih skupinah niso preučevali.
Duloxetine 15 should be used with caution in patients whose conditions could be compromised by an increased heart rate or by an increase in blood pressure.
Previdnost je
Caution should also be exercised when duloxetine is used with medicinal products that may impair its metabolism (see section 4.5).
15 potrebna tudi pri uporabi duloksetina z zdravili, ki lahko poslabšajo presnovo (glejte poglavje 4 5).
In a clinical trial, adverse events seen on abrupt treatment discontinuation occurred in approximately 44% of patients treated with YENTREVE and 24% of patients taking placebo.
V kliničnih preskušanjih so se neželeni učinki ob nenadni prekinitvi zdravljenja pojavili pri približno 45% bolnic, ki so jemale zdravilo YENTREVE in pri 23% bolnic, ki so dobivale placebo.
Depression, suicidal ideation and behaviour Although YENTREVE is not indicated for the treatment of depression, its active ingredient (duloxetine) also exists as an antidepressant medication.
Depresija, samomorilne misli in vedenje Čeprav zdravilo YENTREVE ni indicirano za zdravljenje depresije, njegova zdravilna učinkovina (duloksetin) obstaja tudi kot antidepresivno zdravilo.
If a decision to initiate antidepressant 16 pharmacological therapy is taken, the gradual discontinuation of YENTREVE is recommended (see Section 4.2).
V primeru, da se zdravnik odloči za farmakološko zdravljenje z antidepresivi, svetujemo postopno ukinjanje zdravila YENTREVE (glejte poglavje 4. 2).
CNS medicinal products: caution is advised when YENTREVE is taken in combination with other centrally acting medicinal products or substances, including alcohol and sedative medicinal products (benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).
Zdravila CŽS: če se zdravilo YENTREVE jemlje v kombinaciji z drugimi osrednje delujočimi zdravili ali snovmi, vključno z alkoholom in pomirjevali (benzodiazepini, morfinomimetiki, antipsihotiki, fenobarbitalom, sedativnimi antihistaminiki), priporočamo previdnost.
Duloxetine is a moderate inhibitor of CYP2D6.
17 Zdravila, ki jih presnavlja CYP2D6: duloksetin je zmeren zaviralec CYP2D6.
The co-administration of duloxetine (40 17 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71%, but does not affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is recommended.
Sočasno dajanje duloksetina (40 mg dvakrat dnevno) poveča AUC tolterodina (2 mg dvakrat dnevno) v stanju dinamičnega ravnovesja za 71%, ne vpliva pa na farmakokinetiko njegovega aktivnega 5- hidroksi presnovka, zato ne priporočamo prilagajanja odmerjanja.
18 Table 1 gives the adverse reactions observed from spontaneous reporting and in placebo-controlled clinical trials (comprising a total of 7977 patients, 4371 on duloxetine and 3606 on placebo) in SUI and other lower urinary tract disorders.
Preglednica 1 prikazuje neželene učinke, ki so jih opažali v spontanih poročanjih in v s placebom kontroliranih kliničnih preskušanjih (skupno 7. 976 bolnic, 4. 370 jih je jemalo duloksetin, 3. 606 jih je dobilo placebo) za zdravljenje SUI ali drugih bolezni spodnjih sečil.
The most commonly reported adverse events in patients treated with YENTREVE in clinical trials in SUI and other lower urinary tract disorders were nausea, dry mouthand fatigue -.
Neželeni učinki, o katerih so pri bolnicah, zdravljenih z zdravilom YENTREVE v kliničnih preskušanjih o SUI in drugih boleznih spodnjih sečil, najpogosteje poročali, so bili slabost, suha usta, utrujenost in zaprtje.
20 Very common
sistema
Disorientation Hallucinations Abnormal dreams Apathy Bruxism Orgasm abnormal
Zmanjšanje Bruksizem libida Nenormalen orgazem
Cases of tinnitus have also been reported after treatment discontinuation.
O primerih tinitusa so poročali tudi po prekinitvi zdravljenja. 2O primerih ortostatske hipotenzije in sinkope so poročali zlasti ob začetku zdravljenja.
21 4.9 Overdose
21 4. 9 Preveliko odmerjanje
Using a global improvement scale (PGI), significantly more women
Glede na lestvico splošnega izboljšanja (PGI) je značilno več žensk, ki
22 using duloxetine considered their symptoms of stress incontinence to be improved with treatment compared with women using placebo (64.6% versus 50.1%, p < .001).
22 so jemale duloksetin, ocenilo svoje simptome stresne inkontinence za izboljšane z zdravljenjem, v primerjavi z ženskami, ki so prejemale placebo (64, 6% v primerjavi s 50, 1%, p < 0, 001).
YENTREVE and Prior Continence Surgery: there are limited data that suggest that the benefits of YENTREVE are not diminished in women with stress urinary incontinence who have previously undergone continence surgery.
Zdravilo YENTREVE in predhodno kirurško zdravljenje inkontinence: omejeni podatki kažejo, da koristi zdravila YENTREVE pri bolnicah s stresno urinsko inkontinenco, ki so bile predhodno operirane zaradi inkontinence, niso zmanjšane.
23 Nursing mothers:
23 Doječe matere:
Gelatin Sodium Lauryl Sulfate Titanium Dioxide (E171) Indigo Carmine (E132) Edible Black Ink.
Ovojnica kapsule: želatina natrijev lavrilsulfat titanov dioksid (E171) indigotin (E132) užitno črno črnilo
26 A MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
26 A IMETNIK (I) DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJE
Lilly SA Avenida de la Industria No 30 28108 Alcobendas Madrid Spain
Lilly SA Avenida de la Industria Nº 30 28108 Alcobendas Madrid Španija
Duloxetine
YENTREVE 40 mg trde gastrorezistentne kapsule duloksetin
packs of 28 hard gastro-resistant capsules 56 hard gastro-resistant capsules 98 hard gastro-resistant capsules 140 hard gastro-resistant capsules
28 trdih gastrorezistentnih kapsul 56 trdih gastrorezistentnih kapsul 98 trdih gastrorezistentnih kapsul 140 trdih gastrorezistentnih kapsul
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 30 OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
98 capsules Component of a multipack comprising 2 packs, each containing 98 capsules.
98 kapsul Del večjega pakiranja, sestavljenega iz dveh pakiranj, ki vsebujeta po 98 kapsul.
33 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER WRAPPER LABEL ON MULTIPACKS (2X98 CAPSULES, 40 MG) WRAPPED IN FOIL (INCLUDING BLUE BOX)
33 PODATKI NA ZUNANJI OVOJNINI
35 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS (40 mg hard gastro- resistant capsules)
35 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU (40 mg trde gastrorezistentne kapsule)
Duloxetine
YENTREVE 20 mg trde gastrorezistentne kapsule duloksetin
Packs of 28 hard gastro-resistant capsules Packs of 56 hard gastro-resistant capsules Packs of 98 hard gastro-resistant capsules.
28 trdih gastrorezistentnih kapsul 56 trdih gastrorezistentnih kapsul 98 trdih gastrorezistentnih kapsul
38 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS (20 mg hard gastro- resistant capsules)
38 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU (20 mg trde gastrorezistentne kapsule)
YENTREVE 40 mg hard gastro resistant capsules YENTREVE 20 mg hard gastro resistant capsules Duloxetine (as hydrochloride)
40 NAVODILO ZA UPORABO YENTREVE 40 mg trde gastrorezistentne kapsule YENTREVE 20 mg trde gastrorezistentne kapsule duloksetin (v obliki klorida)
What YENTREVE is and what it is used for 2.
Kaj je zdravilo YENTREVE in za kaj ga uporabljamo 2.
Before you take YENTREVE 3.
Kaj morate vedeti, preden boste vzeli zdravilo YENTREVE 3.
How to take YENTREVE 4.
Kako jemati zdravilo YENTREVE 4.
How to store YENTREVE 6.
Možni neželeni učinki 5 Shranjevanje zdravila YENTREVE 6.
WHAT YENTREVE IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO YENTREVE IN ZA KAJ GA UPORABLJAMO
YENTREVE increases the levels of serotonin and norepinephrine in the nervous system.
Zdravilo YENTREVE zviša nivo serotonina in noradrenalina v živčnem sistemu.
BEFORE YOU TAKE YENTREVE
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO YENTREVE
Do not take YENTREVE
Ne jemljite zdravila YENTREVE
- If you are allergic (hypersensitive) to duloxetine or any of the inactive ingredients of
- Če ste preobčutljivi za (alergični na) duloksetin ali katerokoli pomožno snov zdravila YENTREVE.
- You have a history of seizures (fits).
- Imeli ste epileptične napade (krče).
- You have a history of mania or bipolar disorder.
- Imate ali ste imeli manijo ali bipolarno motnjo.
- You have eye problems such as certain kinds of glaucoma (increased pressure in the eye).
- Imate težave z očmi, kot so določene vrste glavkoma (povišan tlak v očesu).
- You are younger than 18 years.
- Imate tveganje za nizek nivo natrija.
- You are considering stopping YENTREVE (see section 3).
- Premišljujete o prenehanju jemanja zdravila YENTREVE (glejte poglavje 3).
Use in children and adolescents under 18 years of age YENTREVE should not be used for children and adolescents under the age of 18 years.
Uporaba pri otrocih in mladostnikih, mlajših od 18 let Zdravila YENTREVE pri otrocih in mladostnikih, mlajših od 18 let, ne smemo uporabljati.
The main ingredient of YENTREVE, duloxetine, is used in other medicines for other conditions (diabetic neuropathic pain, depression and urinary incontinence).
Duloksetin, glavna zdravilna učinkovina zdravila YENTEREVE se uporablja v drugih zdravilih za zdravljenje drugih bolezni (bolečine diabetične nevropatije, depresije in urinske inkontinence).
42 Monoamine Oxidase Inhibitors (MAOI): you should not take YENTREVE with an MAOI or within 14 days of stopping an MAOI.
Zaviralci monoaminooksidaze (MAOI): zdravila YENTREVE ne smete jemati skupaj z MAOI ali v 14 dneh po prenehanju jemanja MAOI.
Taking an MAOI together with many prescription medicines, including YENTREVE, can cause serious or even life-threatening side effects.
Jemanje MAOI skupaj z mnogimi zdravili na recept, vključno z zdravilom YENTREVE, lahko povzroči resne ali celo smrtno nevarne neželene učinke.
Also, you need to wait at least 5 days after you stop taking YENTREVE before you take an MAOI.
Tudi po prenehanju jemanja zdravila YENTREVE morate počakati vsaj 5 dni, preden lahko vzamete MAOI.
CNS medicines: caution is advised when YENTREVE is taken in combination with other centrally acting medicines or substances, including alcohol and sedative medicines (benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).
42 Zdravila CŽS: če se zdravilo YENTREVE jemlje v kombinaciji z drugimi osrednje delujočimi zdravili ali snovmi, vključno z alkoholom in pomirjevali (benzodiazepini, morfinomimetiki, antipsihotiki, fenobarbitalom, sedativnimi antihistaminiki), priporočamo previdnost.
These medicines increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with YENTREVE, you should see your doctor.
Ta zdravila povečajo tveganje za neželene učinke; če se pojavi kakršenkoli neobičajen simptom ob jemanju katerega od teh zdravil skupaj z zdravilom YENTREVE, obiščite svojega zdravnika.
Taking YENTREVE with food and drink YENTREVE may be taken with or without food.
Jemanje zdravila YENTREVE skupaj s hrano in pijačo Zdravilo YENTREVE lahko vzamete s hrano ali brez nje.
Pregnancy and breast-feeding Tell your doctor if you become pregnant, or you are trying to become pregnant, while you are taking YENTREVE.
Nosečnost in dojenje Če zanosite ali poskušate zanositi, medtem ko jemljete zdravilo YENTREVE, obvestite o tem svojega zdravnika.
Important information about some of the ingredients of YENTREVE YENTREVE contains sucrose.
Pomembne informacije o nekaterih sestavinah zdravila YENTREVE Zdravilo YENTREVE vsebuje saharozo.
HOW TO TAKE YENTREVE
KAKO JEMATI ZDRAVILO YENTREVE
Always take YENTREVE exactly as your doctor has told you.
Pri jemaju zdravila YENTREVE natančno upoštevajte zdravnikova navodila.
The recommended dose of YENTREVE is one capsule of 40 mg twice a day (in the morning and late afternoon/ evening).
Priporočen odmerek zdravila YENTREVE je ena 40 mg kapsula dvakrat dnevno (zjutraj in pozno popoldne/ zvečer).
43 Do not stop taking YENTREVE without talking to your doctor.
Ne prenehajte jemati zdravila YENTREVE, ne da bi se posvetovali s svojim zdravnikom.
If you take more YENTREVE than you should Call your doctor or pharmacist immediately if you take more than the amount of YENTREVE prescribed by your doctor.
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali s farmacevtom.
If you forget to take YENTREVE Do not take a double dose to make up for forgotten doses.
Če ste vzeli večji odmerek zdravila YENTREVE, kot bi smeli
However, if it is time for your next dose, skip the missed dose and take only a single dose as usual.
43 Če vzamete večjo količino zdravila YENTREVE, kot vam je predpisal vaš zdravnik, nemudoma pokličite svojega zdravnika ali farmacevta.
Do not take more than the daily amount of YENTREVE that has been prescribed for you in one day.
Če ste pozabili vzeti zdravilo YENTREVE Ne vzemite dvojnega odmerka, da bi nadomestili pozabljeni odmerek.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Če pozabite vzeti odmerek, ga zaužijte, kakor hitro se spomnite.
If you stop taking YENTREVE Do not stop taking your capsules without the advice of your doctor even if you feel better.
Če ste prenehali jemati zdravilo YENREVE Ne prenehajte jemati svojih kapsul, če vam ni tako svetoval vaš zdravnik, tudi če se bolje počutite.
If your doctor thinks that you no longer need YENTREVE he will ask you to reduce your dose over 2 weeks.
Če bo vaš zdravnik menil, da zdravila YENTREVE ne potrebujete več, vam bo naročil, da 2 tedna postopoma znižujte vaš odmerek.
Some patients, who suddenly stop taking YENTREVE after more than 1 week of therapy, have had symptoms such as dizziness, tingling feelings like pins and needles, sleep disturbances (vivid dreams, nightmares, inability to sleep), feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), tremor (shakiness), headaches, feeling irritable, diarrhoea, excessive sweating or vertigo..
Nekatere bolnice, ki se nenadoma prenehale jemati zdravilo YENTREVE po več kot 1 tednu zdravljenja, so imele simptome, kot so omotica, ščemenje (občutek zbadanja z iglami), motnje spanja (žive sanje, nočne more, nezmožnost spanja), občutek nemira ali razburjenosti, občutek strahu, slabost ali bruhanje, tresenje, glavoboli, občutek razdraženosti, driska, prekomerno znojenje ali vrtoglavica.
Like all medicines, YENTREVE can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo YENTREVE neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.